Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edgemont Pharmaceuticals LlcfiledCriticalEdgemont Pharmaceuticals Llc
Publication of AR094391A1publicationCriticalpatent/AR094391A1/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Una composición farmacéutica para entregar lorazepam de un modo prolongado se alcanza con perlas farmacéuticas de lorazepam de liberación prolongada. La composición típicamente contiene perlas de lorazepam de liberación sostenida y perlas de lorazepam de liberación sostenida retardada. La composición puede proveer una dosificación de una vez por día que mantiene un efecto terapéutico de 24 horas bajo condiciones de estado estacionario.A pharmaceutical composition for delivering lorazepam in a prolonged manner is achieved with long-release lorazepam pharmaceutical beads. The composition typically contains sustained release lorazepam pearls and delayed sustained release lorazepam pearls. The composition can provide a dosage once a day that maintains a therapeutic effect of 24 hours under steady state conditions.
ARP140100068A2013-01-092014-01-08
LORAZEPAM FORMULATIONS OF SUSTAINED RELEASE
AR094391A1
(en)
STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS
Stable anti-tuberculosis pharmaceutical composition in a form of a redispersible tablet comprising isoniazid granules and rifapentin granules and their preparation process
Use of an extended-release dosage form of arbaclofen comprising a first dose and a second dose to be administered in a 24-hour period, where the first dose is administered in the fed state and the second dose in the fasted state; or the first dose in the fasted state and the second dose in the fed state